Pharma's Almanac

4780 Articles Available

1 200

Human Genome

Tecan’s First Virtual Genomics Symposium

PR-M11-20-036

Acquisition

Thermo Fisher Scientific Acquires Viral Vector Manufacturing Business from Novasep

PR-M11-20-035

Expansion

Cognate BioServices and its Gene Therapy Division Cobra Biologics Announce Major Expansion of Manufacturing Facilities in US and Europe

PR-M11-20-034

Screening Service

Hovione Launches ASD-HIPROS the Most Advanced Screening Service for Optimal Spray Dried Dispersions Formulation

PR-M11-20-033

HPAPI

A Successful Approach for Managing Unexpected Increases in Potency for HPAPIs

PAO-01-21-CL-01

Cell Therapy

Allogeneic T Cell Therapies: Efficient Commercial Manufacturing Readiness using “Manufacturing by Design” Methodology

PAO-12-20-CL-01

Strategic Partnership

PharmaBlock Enters Strategic Partnership with Ascentage Pharma

PR-M11-20-032

COVID-19 Vaccine

HALIX Signs Agreement With AstraZeneca For Commercial Manufacture Of COVID-19 Vaccine

PR-M11-20-031

Strategic Collaboration

Bayer and Atara Biotherapeutics Enter Strategic Collaboration for Mesothelin-Targeted CAR T-cell Therapies for Solid Tumors

PR-M11-20-030

Cover Story

Facing the Challenges of the COVID-19 Pandemic: Rentschler Biopharma

PAP-Q4-20-CL-028

Nice Insight Overview

Delivering Vaccines During a Pandemic

PAP-Q4-20-NI-001

Single-Use Technology

Stainless Steel to Single-Use: How to Adapt to the Changing Landscape in SUT

PAP-Q4-20-CL-004

Industry Leader

Shaping the Future of Biopharma Through Next-Generation Contract Drug Manufacturing

PAP-Q4-20-CL-023

Clinical Trials

Modern Strategies for Dermatology Clinical Trials

PAP-Q4-20-CL-021

Hot Melt Extrusion

Solving Solubility Challenges with a Polyvinyl Alcohol Excipient and Hot Melt Extrusion

PAP-Q4-20-CL-016

COVID-19 vaccine

How COVID-19 Is Reshaping Vaccine Development: Innovations in Vaccine Technology and Partnerships

PAP-Q4-20-CL-007

Digital Transformation

Seamlessly Sharing Supply Chain Information to Deliver Measurable Efficiencies for Clients

PAP-Q4-20-CL-020

Personalized Medicines

Disruptive Technologies in Life Sciences: Personalized Medicines

PAP-Q4-20-CL-009

Corporate Social Responsibility

Life Imitating Science: Arranta Bio’s Commitment to Corporate Social Responsibility and Diversity

PAP-Q4-20-CL-002

Extractables & Leachables

Aiding Material Qualification and Risk Assessment for Single-Use Biomanufacturing

PAP-Q4-20-CL-015

Virtual Trade Shows

Meeting the Challenges of the Pandemic through Virtual Trade Shows

PAP-Q4-20-CL-011

Small Molecule

The Importance of a Global Leader in Small Molecule Manufacturing During the COVID-19 Pandemic

PAP-Q4-20-CL-025

Digital Marketing

Creating Quality Content for Effective Digital Marketing

PAP-Q4-20-CL-024

Modular Facilities

Controlling the Cost of Ownership with Modular Facility Construction

PAP-Q4-20-CL-010